☒
|
Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
|
☐
|
Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Delaware
|
|
22-1760285
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. employer identification no.)
|
150 Clove Road, Little Falls, New Jersey
|
|
07424
|
(Address of principal executive offices)
|
|
(Zip code)
|
Title of each class
|
|
Trading symbol
|
|
Name of exchange on which registered
|
Common Stock, $0.10 par value
|
|
CMD
|
|
New York Stock Exchange
|
Large accelerated filer ☒
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller reporting company ☐
|
Emerging growth company ☐
|
|
|
Page No.
|
|
|
|
Item 1.
|
||
Item 1A.
|
||
Item 1B.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
|
|
Item 5.
|
||
Item 6.
|
Selected Consolidated Financial Data
|
|
Item 7.
|
||
Item 7A.
|
||
Item 8.
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
Item 9.
|
||
Item 9A.
|
||
Item 9B.
|
||
|
|
|
Item 10.
|
||
Item 11.
|
||
Item 12.
|
||
Item 13.
|
||
Item 14.
|
||
|
|
|
Item 15.
|
||
Item 16.
|
||
Signatures.
|
•
|
a full range of automated endoscope reprocessing systems,
|
•
|
high-level disinfectants and sterilants,
|
•
|
detergents,
|
•
|
leak testing and manual cleaning products,
|
•
|
storage cabinets and transport systems,
|
•
|
manual cleaning products,
|
•
|
endoscope process tracking products, including software,
|
•
|
other consumables, accessories and supplies used to high-level disinfect rigid endoscopes, flexible endoscopes and other instrumentation, and
|
•
|
technical maintenance service on our products.
|
•
|
CO2 and water irrigation pumps and disposable procedure kits,
|
•
|
sterile irrigation tubing, and
|
•
|
single-use valves.
|
•
|
central dialysis water purification systems,
|
•
|
portable dialysis water purification systems,
|
•
|
bicarbonate mixing systems,
|
•
|
hollow fiber filters and other filtration and separation products,
|
•
|
liquid disinfectants and cold sterilization products,
|
•
|
“dry fog” products,
|
•
|
room temperature sterilization equipment and services, and
|
•
|
clean-room certification and decontamination services.
|
•
|
sterility assurance products such as biological indicators, chemical integrators and sterilization pouches,
|
•
|
consumables such as towels, bibs, tray liners and sponges,
|
•
|
nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks,
|
•
|
personal barrier products such as face masks, shields, and hand protection products such as hand sanitizers and germicidal wipes,
|
•
|
cleaning solutions, high level disinfectants and surface disinfectants,
|
•
|
waterline treatment products for maintaining safe dental unit waterlines,
|
•
|
amalgam separators,
|
•
|
treatment accessories such as saliva ejectors, evacuator tips and plastic cups, and
|
•
|
preventatives such as prophy angles and prophy paste.
|
•
|
hemodialysis concentrates and other ancillary supplies,
|
•
|
medical device reprocessing systems, and
|
•
|
sterilants and disinfectants.
|
•
|
identify and acquire appropriate products and businesses, including obtaining required regulatory (such as antitrust) approvals,
|
•
|
obtain financing for acquisitions on terms that are favorable or acceptable,
|
•
|
integrate acquired operations, personnel, products, technologies and regulatory procedures into our organization effectively,
|
•
|
retain and motivate key personnel and retain the customers and suppliers of acquired companies,
|
•
|
realize expected benefits such as perceived tax benefits and synergies, and
|
•
|
successfully promote and increase sales and profits of acquired product lines.
|
•
|
delays in realizing the benefits of the transactions, including achievement of anticipated operating efficiencies and synergies and other transaction benefits as well as forecasted sales and earnings,
|
•
|
diversion of management’s time and attention,
|
•
|
difficulties in implementing and maintaining uniform standards, controls, procedures and policies, and
|
•
|
risks associated with the assumption of contingent or undisclosed liabilities of acquired companies.
|
Location
|
|
Owned/Leased
|
|
Purpose
|
|
Square
Footage
|
|
Segment
|
Plymouth, MN (multiple)
|
|
Owned
|
|
Administrative, sales, R&D & land
|
|
267,000
|
|
Medical, Dialysis, Life Sciences
|
Pomezia, Italy
|
|
Owned
|
|
Manufacturing, warehousing & administrative
|
|
156,000
|
|
Medical
|
Henrietta, NY
|
|
Leased
|
|
Manufacturing, warehousing & administrative
|
|
134,000
|
|
Dental
|
Hauppauge, NY
|
|
Owned
|
|
Administrative, sales, manufacturing & warehousing
|
|
65,000
|
|
Dental
|
Conroe, TX (multiple)
|
|
Owned
|
|
Administrative, sales, R&D, manufacturing, warehousing & training
|
|
72,000
|
|
Medical
|
Hauppauge, NY
|
|
Leased
|
|
Warehousing
|
|
52,000
|
|
Dental
|
Sharon, PA
|
|
Owned
|
|
Manufacturing & warehousing
|
|
50,000
|
|
Dental
|
Southend-on-Sea, U.K.
|
|
Owned
|
|
Manufacturing, warehousing & administrative
|
|
49,500
|
|
Medical
|
Plymouth, MN
|
|
Leased
|
|
Warehousing
|
|
154,000
|
|
Life Sciences
|
Conroe, TX (multiple)
|
|
Leased
|
|
Executive, sales, administrative, R&D & training
|
|
42,000
|
|
Medical
|
Lawrenceville, GA
|
|
Leased
|
|
Manufacturing & warehousing
|
|
41,000
|
|
Dental
|
Rush, NY
|
|
Owned
|
|
Manufacturing, warehousing, administrative & sales
|
|
38,000
|
|
Dental
|
Phoenix, AZ
|
|
Leased
|
|
Manufacturing, administrative & warehousing
|
|
37,000
|
|
Dental
|
Gersthofen, Germany
|
|
Leased
|
|
Manufacturing, administrative & warehousing
|
|
35,000
|
|
Medical
|
Santa Fe Springs, CA
|
|
Leased
|
|
Manufacturing & warehousing
|
|
32,000
|
|
Dental
|
Heerlen, the Netherlands
|
|
Leased
|
|
Sales, service, warehousing & distribution
|
|
26,000
|
|
All segments
|
Lowell, MA
|
|
Leased
|
|
Sales, administrative, warehousing & regeneration
|
|
26,000
|
|
Life Sciences
|
Skippack, PA
|
|
Leased
|
|
Sales, administrative, warehousing and regeneration
|
|
23,000
|
|
Life Sciences
|
Period
|
Total number of shares purchased
|
|
Average price paid per share
|
|
Total number of shares purchased as part of publicly announced plans or programs
|
|
Maximum number of shares that may yet be under the plan or programs
|
|||||
May 1 - May 31
|
22
|
|
(1)
|
$
|
68.94
|
|
|
—
|
|
|
—
|
|
June 1 - June 30
|
224
|
|
(1)
|
$
|
71.01
|
|
|
—
|
|
|
—
|
|
July 1 - July 31
|
1,094
|
|
(1)
|
$
|
87.85
|
|
|
—
|
|
|
—
|
|
|
1,340
|
|
(1)
|
$
|
84.73
|
|
|
—
|
|
|
—
|
|
(1)
|
The Company does not currently have a share repurchase program. All of the shares purchased during the fourth quarter of fiscal 2019 represent shares surrendered to the Company to pay employee withholding taxes due upon the vesting of restricted stock.
|
|
July 31,
|
||||||||||||||||||||||
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
2018
|
|
2019
|
||||||||||||
Cantel Medical Corp.(1)
|
$
|
100.00
|
|
|
$
|
164.02
|
|
|
$
|
200.47
|
|
|
$
|
222.59
|
|
|
$
|
278.58
|
|
|
$
|
277.99
|
|
Russell 2000 Index
|
$
|
100.00
|
|
|
$
|
112.03
|
|
|
$
|
112.03
|
|
|
$
|
132.70
|
|
|
$
|
157.56
|
|
|
$
|
149.74
|
|
Dow Jones U.S. Health Care Equipment & Services Index
|
$
|
100.00
|
|
|
$
|
131.02
|
|
|
$
|
138.64
|
|
|
$
|
160.32
|
|
|
$
|
200.55
|
|
|
$
|
221.78
|
|
(1)
|
$100 invested on July 31, 2014 in Cantel Medical Corp.'s common stock or index, including reinvestment of dividends. Indexes are calculated on month-end basis.
|
|
Year Ended July 31,
|
||||||||||||||||||
Consolidated Statements of Income Data
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
Net sales
|
$
|
918,155
|
|
|
$
|
871,922
|
|
|
$
|
770,157
|
|
|
$
|
664,755
|
|
|
$
|
565,004
|
|
Cost of Sales
|
490,701
|
|
|
457,951
|
|
|
402,997
|
|
|
355,569
|
|
|
311,537
|
|
|||||
Gross profit
|
427,454
|
|
|
413,971
|
|
|
367,160
|
|
|
309,186
|
|
|
253,467
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Income from operations
|
83,519
|
|
|
121,664
|
|
|
110,410
|
|
|
97,251
|
|
|
80,761
|
|
|||||
Interest expense, net
|
9,505
|
|
|
5,289
|
|
|
4,303
|
|
|
3,320
|
|
|
2,364
|
|
|||||
Other income
|
(1,305
|
)
|
|
(1,138
|
)
|
|
(126
|
)
|
|
—
|
|
|
—
|
|
|||||
Loss on sale of business
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,206
|
|
|||||
Income before income taxes
|
75,319
|
|
|
117,513
|
|
|
106,233
|
|
|
93,931
|
|
|
76,191
|
|
|||||
Income taxes
|
20,277
|
|
|
26,472
|
|
|
34,855
|
|
|
33,978
|
|
|
28,238
|
|
|||||
Net income
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
|
$
|
59,953
|
|
|
$
|
47,953
|
|
Earnings Per Share Data
|
|
|
|
|
|
|
|
|
|
||||||||||
Weighted average basic shares outstanding
|
41,700,926
|
|
|
41,567,722
|
|
|
41,468,487
|
|
|
41,344,013
|
|
|
41,139,467
|
|
|||||
Weighted average diluted shares outstanding
|
41,757,116
|
|
|
41,635,078
|
|
|
41,542,765
|
|
|
41,390,194
|
|
|
41,202,600
|
|
|||||
Basic earnings per common share
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
|
$
|
1.44
|
|
|
$
|
1.16
|
|
Diluted earnings per common share
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
|
$
|
1.44
|
|
|
$
|
1.15
|
|
Dividends per common share
|
$
|
0.20
|
|
|
$
|
0.17
|
|
|
$
|
0.14
|
|
|
$
|
0.12
|
|
|
$
|
0.10
|
|
Other Financial Data
|
|
|
|
|
|
|
|
|
|
||||||||||
Net cash provided by operating activities
|
$
|
66,931
|
|
|
125,912
|
|
|
$
|
108,193
|
|
|
$
|
80,268
|
|
|
$
|
59,070
|
|
|
Capital expenditures
|
95,438
|
|
|
37,698
|
|
|
27,065
|
|
|
18,889
|
|
|
12,760
|
|
|||||
Acquisition of businesses, net of cash acquired
|
40,644
|
|
|
87,488
|
|
|
70,044
|
|
|
94,528
|
|
|
43,567
|
|
|||||
Depreciation
|
21,510
|
|
|
17,473
|
|
|
15,045
|
|
|
11,989
|
|
|
10,692
|
|
|||||
Amortization
|
20,849
|
|
|
17,357
|
|
|
18,407
|
|
|
13,095
|
|
|
13,265
|
|
|||||
|
July 31,
|
||||||||||||||||||
Consolidated Balance Sheets Data
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
Cash and cash equivalents
|
$
|
44,535
|
|
|
$
|
94,097
|
|
|
$
|
36,584
|
|
|
$
|
28,367
|
|
|
$
|
31,720
|
|
Total assets
|
1,070,366
|
|
|
963,708
|
|
|
786,373
|
|
|
694,532
|
|
|
584,031
|
|
|||||
Working capital
|
200,396
|
|
|
203,460
|
|
|
150,592
|
|
|
126,407
|
|
|
117,737
|
|
|||||
Long-term debt (excluding debt issuance costs)
|
233,000
|
|
|
200,000
|
|
|
126,000
|
|
|
116,000
|
|
|
78,500
|
|
|||||
Stockholders’ equity
|
661,537
|
|
|
608,867
|
|
|
523,932
|
|
|
454,370
|
|
|
406,633
|
|
•
|
Net sales increased by 5.3% to $918,155 from $871,922, with organic sales growth of 3.9%,
|
•
|
Net income decreased by 39.5% to $55,042 from $91,041, and
|
•
|
Earnings per diluted share decreased by 39.6% to $1.32 from $2.18.
|
•
|
Non-GAAP net income decreased by 5.1% to $98,999 from $104,346,
|
•
|
Non-GAAP earnings per diluted share decreased by 5.4% to $2.37 from $2.51, and
|
•
|
Adjusted EBITDAS decreased by 1.9% to $174,848 from $178,270.
|
|
Year Ended July 31,
|
|
Percentage Change
|
||||||||||||||||||||
Statement of income data
|
2019
|
|
2018
|
|
2017
|
|
2019 / 2018
|
|
2018 / 2017
|
||||||||||||||
Net sales
|
$
|
918,155
|
|
100.0
|
%
|
|
$
|
871,922
|
|
100.0
|
%
|
|
$
|
770,157
|
|
100.0
|
%
|
|
5.3
|
%
|
|
13.2
|
%
|
Cost of sales
|
490,701
|
|
53.4
|
%
|
|
457,951
|
|
52.5
|
%
|
|
402,997
|
|
52.3
|
%
|
|
7.2
|
%
|
|
13.6
|
%
|
|||
Gross profit
|
427,454
|
|
46.6
|
%
|
|
413,971
|
|
47.5
|
%
|
|
367,160
|
|
47.7
|
%
|
|
3.3
|
%
|
|
12.7
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Selling
|
140,232
|
|
15.3
|
%
|
|
129,642
|
|
14.9
|
%
|
|
116,113
|
|
15.1
|
%
|
|
8.2
|
%
|
|
11.7
|
%
|
|||
General and administrative
|
172,383
|
|
18.8
|
%
|
|
138,019
|
|
15.8
|
%
|
|
122,270
|
|
15.9
|
%
|
|
24.9
|
%
|
|
12.9
|
%
|
|||
Research and development
|
31,320
|
|
3.4
|
%
|
|
24,646
|
|
2.8
|
%
|
|
18,367
|
|
2.4
|
%
|
|
27.1
|
%
|
|
34.2
|
%
|
|||
Total operating expenses
|
343,935
|
|
37.5
|
%
|
|
292,307
|
|
33.5
|
%
|
|
256,750
|
|
33.4
|
%
|
|
17.7
|
%
|
|
13.8
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Income from operations
|
83,519
|
|
9.1
|
%
|
|
121,664
|
|
14.0
|
%
|
|
110,410
|
|
14.3
|
%
|
|
(31.4
|
)%
|
|
10.2
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Interest expense, net
|
9,505
|
|
1.0
|
%
|
|
5,289
|
|
0.6
|
%
|
|
4,303
|
|
0.5
|
%
|
|
79.7
|
%
|
|
22.9
|
%
|
|||
Other income
|
(1,305
|
)
|
(0.1
|
)%
|
|
(1,138
|
)
|
(0.1
|
)%
|
|
(126
|
)
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|||
Income before income taxes
|
75,319
|
|
8.2
|
%
|
|
117,513
|
|
13.5
|
%
|
|
106,233
|
|
13.8
|
%
|
|
(35.9
|
)%
|
|
10.6
|
%
|
|||
Income taxes
|
20,277
|
|
2.2
|
%
|
|
26,472
|
|
3.1
|
%
|
|
34,855
|
|
4.5
|
%
|
|
(23.4
|
)%
|
|
(24.1
|
)%
|
|||
Net income
|
$
|
55,042
|
|
6.0
|
%
|
|
$
|
91,041
|
|
10.4
|
%
|
|
$
|
71,378
|
|
9.3
|
%
|
|
(39.5
|
)%
|
|
27.5
|
%
|
|
Year Ended July 31,
|
|||||||||||||||||||
Net sales by segment
|
2019
|
|
2018
|
|
2017
|
|||||||||||||||
Medical
|
$
|
523,669
|
|
|
57.0
|
%
|
|
$
|
473,937
|
|
|
54.4
|
%
|
|
$
|
398,773
|
|
|
51.8
|
%
|
Life Sciences
|
201,022
|
|
|
21.9
|
%
|
|
217,030
|
|
|
24.9
|
%
|
|
196,446
|
|
|
25.5
|
%
|
|||
Dental
|
161,608
|
|
|
17.6
|
%
|
|
149,360
|
|
|
17.1
|
%
|
|
144,457
|
|
|
18.7
|
%
|
|||
Dialysis
|
31,856
|
|
|
3.5
|
%
|
|
31,595
|
|
|
3.6
|
%
|
|
30,481
|
|
|
4.0
|
%
|
|||
Total net sales
|
$
|
918,155
|
|
|
100.0
|
%
|
|
$
|
871,922
|
|
|
100.0
|
%
|
|
$
|
770,157
|
|
|
100.0
|
%
|
Net sales by geography
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
United States
|
$
|
665,661
|
|
|
72.5
|
%
|
|
$
|
643,744
|
|
|
73.9
|
%
|
|
$
|
599,657
|
|
|
77.9
|
%
|
International
|
252,494
|
|
|
27.5
|
%
|
|
228,178
|
|
|
26.1
|
%
|
|
170,500
|
|
|
22.1
|
%
|
|||
Total net sales
|
$
|
918,155
|
|
|
100.0
|
%
|
|
$
|
871,922
|
|
|
100.0
|
%
|
|
$
|
770,157
|
|
|
100.0
|
%
|
|
Year Ended July 31,
|
|||||||||||||||||||
Income from operations
|
2019
|
|
2018
|
|
2017
|
|||||||||||||||
Medical
|
$
|
98,356
|
|
|
18.8
|
%
|
|
$
|
86,833
|
|
|
18.3
|
%
|
|
$
|
73,440
|
|
|
18.4
|
%
|
Life Sciences
|
20,552
|
|
|
10.2
|
%
|
|
36,803
|
|
|
17.0
|
%
|
|
33,159
|
|
|
16.9
|
%
|
|||
Dental
|
22,289
|
|
|
13.8
|
%
|
|
30,004
|
|
|
20.1
|
%
|
|
28,000
|
|
|
19.4
|
%
|
|||
Dialysis
|
4,922
|
|
|
15.5
|
%
|
|
7,380
|
|
|
23.4
|
%
|
|
8,154
|
|
|
26.8
|
%
|
|||
Operating income by segment
|
146,119
|
|
|
15.9
|
%
|
|
161,020
|
|
|
18.5
|
%
|
|
142,753
|
|
|
18.5
|
%
|
|||
General corporate expenses
|
62,600
|
|
|
6.8
|
%
|
|
39,356
|
|
|
4.5
|
%
|
|
32,343
|
|
|
4.2
|
%
|
|||
Income from operations
|
$
|
83,519
|
|
|
9.1
|
%
|
|
$
|
121,664
|
|
|
14.0
|
%
|
|
$
|
110,410
|
|
|
14.3
|
%
|
|
July 31,
|
||||||||||||||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||||||||||||||
Net income/Diluted EPS, as reported
|
$
|
55,042
|
|
|
$
|
1.32
|
|
|
$
|
91,041
|
|
|
$
|
2.18
|
|
|
$
|
71,378
|
|
|
$
|
1.71
|
|
Intangible amortization, net of tax(1)
|
16,021
|
|
|
0.38
|
|
|
13,267
|
|
|
0.32
|
|
|
12,800
|
|
|
0.30
|
|
||||||
Acquisition-related items, net of tax(2)
|
9,689
|
|
|
0.23
|
|
|
2,835
|
|
|
0.07
|
|
|
1,533
|
|
|
0.04
|
|
||||||
Restructuring-related charges, net of tax(3)
|
18,015
|
|
|
0.43
|
|
|
4,658
|
|
|
0.11
|
|
|
2,057
|
|
|
0.05
|
|
||||||
Litigation matters, net of tax(1)
|
134
|
|
|
—
|
|
|
1,637
|
|
|
0.04
|
|
|
—
|
|
|
—
|
|
||||||
CEO retirement costs, net of tax(1)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,213
|
|
|
0.03
|
|
||||||
Loss on debt extinguishment, net of tax(4)
|
—
|
|
|
—
|
|
|
91
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Gain on disposition of business, net of tax(5)
|
(943
|
)
|
|
(0.02
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Resolution of contingent liability(5)
|
—
|
|
|
—
|
|
|
(1,138
|
)
|
|
(0.03
|
)
|
|
—
|
|
|
—
|
|
||||||
Excess tax benefits(6)
|
(584
|
)
|
|
(0.01
|
)
|
|
(2,173
|
)
|
|
(0.05
|
)
|
|
(2,241
|
)
|
|
(0.05
|
)
|
||||||
Tax matters(6)
|
1,625
|
|
|
0.04
|
|
|
(5,872
|
)
|
|
(0.13
|
)
|
|
—
|
|
|
—
|
|
||||||
Non-GAAP net income/Non-GAAP diluted EPS
|
$
|
98,999
|
|
|
$
|
2.37
|
|
|
$
|
104,346
|
|
|
$
|
2.51
|
|
|
$
|
86,740
|
|
|
$
|
2.08
|
|
(1)
|
Amounts were recorded in general and administrative expenses.
|
(2)
|
In fiscal 2019, pre-tax acquisition-related items of $351 were recorded in net sales, $537 were recorded in cost of sales and $12,241 were recorded in general and administrative expenses. In fiscal 2018, pre-tax acquisition-related items of $893 were recorded in cost of sales and $3,154 were recorded in general and administrative expenses. In fiscal 2017, pre-tax acquisition-related items of $353 were recorded in cost of sales and $2,094 were recorded in general and administrative expenses.
|
(3)
|
In fiscal 2019, pre-tax restructuring-related items of $2,243 were recorded in cost of sales and $21,507 were recorded in general and administrative expenses. In fiscal 2018, pre-tax restructuring-related items of $1,517 were recorded in cost of sales and $3,814 were recorded in general and administrative expenses. In fiscal 2017, pre-tax restructuring-related items of $3,284 were recorded in general and administrative expenses.
|
(4)
|
Amounts were recorded in interest expense, net.
|
(5)
|
Amounts were recorded in other income.
|
(6)
|
Amounts were recorded in income taxes.
|
|
July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Net income, as reported
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
Interest expense, net
|
9,505
|
|
|
5,289
|
|
|
4,303
|
|
|||
Income taxes
|
20,277
|
|
|
26,472
|
|
|
34,855
|
|
|||
Depreciation
|
21,510
|
|
|
17,473
|
|
|
15,045
|
|
|||
Amortization
|
20,849
|
|
|
17,357
|
|
|
18,407
|
|
|||
Loss on disposal of fixed assets
|
1,592
|
|
|
768
|
|
|
966
|
|
|||
Stock-based compensation expense
|
15,562
|
|
|
9,615
|
|
|
8,844
|
|
|||
EBITDAS
|
144,337
|
|
|
168,015
|
|
|
153,798
|
|
|||
Acquisition-related items
|
13,129
|
|
|
4,047
|
|
|
2,447
|
|
|||
Restructuring-related charges(1)
|
18,524
|
|
|
5,001
|
|
|
2,760
|
|
|||
Litigation matters
|
163
|
|
|
2,345
|
|
|
—
|
|
|||
CEO retirement costs(2)
|
—
|
|
|
—
|
|
|
1,937
|
|
|||
Gain on disposition of business
|
(1,305
|
)
|
|
—
|
|
|
—
|
|
|||
Resolution of contingent liability
|
—
|
|
|
(1,138
|
)
|
|
—
|
|
|||
Adjusted EBITDAS
|
$
|
174,848
|
|
|
$
|
178,270
|
|
|
$
|
160,942
|
|
(1)
|
Excludes stock-based compensation expense.
|
(2)
|
For comparative purposes, we have revised the amounts associated with CEO retirement costs for the twelve months ended July 31, 2017 to exclude stock-based compensation expense which was reported in “Stock-based compensation expense” above.
|
|
July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Long-term debt (excluding debt issuance costs)
|
$
|
233,000
|
|
|
$
|
200,000
|
|
|
$
|
126,000
|
|
Less cash and cash equivalents
|
(44,535
|
)
|
|
(94,097
|
)
|
|
(36,584
|
)
|
|||
Net debt
|
$
|
188,465
|
|
|
$
|
105,903
|
|
|
$
|
89,416
|
|
|
|
Net Sales
|
|
Medical
Net Sales
|
|
Life Sciences
Net Sales
|
|
Dental
Net Sales
|
|
Dialysis
Net Sales
|
|||||
Net sales growth
|
|
5.3
|
%
|
|
10.5
|
%
|
|
(7.4
|
)%
|
|
8.2
|
%
|
|
0.8
|
%
|
Impact due to foreign currency translation
|
|
1.0
|
%
|
|
1.7
|
%
|
|
0.3
|
%
|
|
—
|
%
|
|
0.2
|
%
|
Sales related to acquisitions
|
|
(2.4
|
)%
|
|
(0.7
|
)%
|
|
(2.2
|
)%
|
|
(8.4
|
)%
|
|
—
|
%
|
Organic sales growth
|
|
3.9
|
%
|
|
11.5
|
%
|
|
(9.3
|
)%
|
|
(0.2
|
)%
|
|
1.0
|
%
|
|
Year Ended July 31,
|
||||||||||||||||||||||||||
|
2020
|
|
2021
|
|
2022
|
|
2023
|
|
2024
|
|
Thereafter
|
|
Total
|
||||||||||||||
Maturity of the credit facility(1)
|
$
|
10,000
|
|
|
$
|
10,000
|
|
|
$
|
10,000
|
|
|
$
|
203,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
233,000
|
|
Expected interest payments under the credit facility
|
8,663
|
|
|
8,315
|
|
|
7,967
|
|
|
7,000
|
|
|
—
|
|
|
—
|
|
|
31,945
|
|
|||||||
Minimum commitments under noncancelable operating leases
|
9,099
|
|
|
7,671
|
|
|
6,021
|
|
|
5,659
|
|
|
5,159
|
|
|
15,251
|
|
|
48,860
|
|
|||||||
Contingent consideration
|
1,411
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,411
|
|
|||||||
Other long-term obligations(2)
|
353
|
|
|
836
|
|
|
73
|
|
|
240
|
|
|
—
|
|
|
—
|
|
|
1,502
|
|
|||||||
Total contractual obligations
|
$
|
29,526
|
|
|
$
|
26,822
|
|
|
$
|
24,061
|
|
|
$
|
215,899
|
|
|
$
|
5,159
|
|
|
$
|
15,251
|
|
|
$
|
316,718
|
|
(1)
|
Does not include anticipated required payments under the Delayed Draw Facility related to the financing of the Hu-Friedy acquisition. However, anticipated payments will be $7,125, $9,500, $9,500 and $373,875 for fiscal 2020, 2021, 2022 and 2023, respectively.
|
(2)
|
Includes uncertain tax positions.
|
•
|
We tested the effectiveness of controls over the valuation of the customer relationship intangible assets, including management’s controls over forecasts of future cash flows and the selection of the customer attrition rates, terminal growth rates and discount rates.
|
•
|
We assessed the reasonableness of fiscal year 2019 forecasted cash flows of revenues and operating margins by comparing them to the acquired entities actual 2019 cash flows.
|
•
|
We assessed the reasonableness of the forecasted revenue growth rates and operating margins over the cash flow forecast period by comparing them to the acquired entities’ actual revenue growth rates and operating margins during the most recent historical periods.
|
•
|
We performed sensitivity analyses of the significant assumptions used in the valuation model to evaluate the change in fair value resulting from changes in the significant assumptions.
|
•
|
With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodologies; (2) terminal growth rates by comparing them to industry growth rates and the projected nominal gross domestic product (GDP) growth rate; (3) customer attrition rates by testing the mathematical accuracy of the rates used and comparing them to historical customer data; and (4) discount rates, which included testing the source information underlying the determination of the discount rates, testing the mathematical accuracy of the calculations, and developing a range of independent estimates and comparing those to the discount rates selected by management.
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Assets
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
44,535
|
|
|
$
|
94,097
|
|
Accounts receivable, net of allowance for doubtful accounts of $2,322 and $1,149
|
146,910
|
|
|
118,642
|
|
||
Inventories, net
|
138,234
|
|
|
107,592
|
|
||
Prepaid expenses and other current assets
|
20,920
|
|
|
17,912
|
|
||
Income taxes receivable
|
1,197
|
|
|
—
|
|
||
Total current assets
|
351,796
|
|
|
338,243
|
|
||
|
|
|
|
||||
Property and equipment, net
|
185,242
|
|
|
111,417
|
|
||
Intangible assets, net
|
141,513
|
|
|
137,361
|
|
||
Goodwill
|
378,109
|
|
|
368,027
|
|
||
Other assets
|
9,425
|
|
|
5,749
|
|
||
Deferred income taxes
|
4,281
|
|
|
2,911
|
|
||
Total assets
|
$
|
1,070,366
|
|
|
$
|
963,708
|
|
|
|
|
|
||||
Liabilities and stockholders’ equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
39,450
|
|
|
$
|
34,258
|
|
Compensation payable
|
32,762
|
|
|
30,595
|
|
||
Accrued expenses
|
38,545
|
|
|
28,525
|
|
||
Deferred revenue
|
27,840
|
|
|
28,614
|
|
||
Current portion of long-term debt
|
10,000
|
|
|
10,000
|
|
||
Income taxes payable
|
2,803
|
|
|
2,791
|
|
||
Total current liabilities
|
151,400
|
|
|
134,783
|
|
||
|
|
|
|
||||
Long-term debt
|
220,851
|
|
|
187,302
|
|
||
Deferred income taxes
|
29,278
|
|
|
27,624
|
|
||
Other long-term liabilities
|
7,300
|
|
|
5,132
|
|
||
Total liabilities
|
408,829
|
|
|
354,841
|
|
||
Commitments and Contingencies (Note 12)
|
|
|
|
|
|
||
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
|
||
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued
|
—
|
|
|
—
|
|
||
Common Stock, par value $.10 per share; Authorized 75,000,000 shares; issued 46,362,902 shares and outstanding 41,771,228 shares as of July 31, 2019; issued 46,243,582 shares and outstanding 41,706,084 shares as of July 31, 2018
|
4,636
|
|
|
4,624
|
|
||
Additional paid-in capital
|
204,795
|
|
|
184,212
|
|
||
Retained earnings
|
539,097
|
|
|
491,540
|
|
||
Accumulated other comprehensive loss
|
(22,197
|
)
|
|
(11,456
|
)
|
||
Treasury Stock, at cost; 4,591,674 shares as of July 31, 2019; 4,537,498 shares as of July 31, 2018
|
(64,794
|
)
|
|
(60,053
|
)
|
||
Total stockholders’ equity
|
661,537
|
|
|
608,867
|
|
||
Total liabilities and stockholders’ equity
|
$
|
1,070,366
|
|
|
$
|
963,708
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Net sales
|
|
|
|
|
|
|
|
|
|||
Product sales
|
$
|
795,403
|
|
|
$
|
765,158
|
|
|
$
|
684,678
|
|
Product service
|
122,752
|
|
|
106,764
|
|
|
85,479
|
|
|||
Total net sales
|
918,155
|
|
|
871,922
|
|
|
770,157
|
|
|||
|
|
|
|
|
|
||||||
Cost of sales
|
|
|
|
|
|
|
|
|
|||
Product sales
|
406,514
|
|
|
385,597
|
|
|
343,641
|
|
|||
Product service
|
84,187
|
|
|
72,354
|
|
|
59,356
|
|
|||
Total cost of sales
|
490,701
|
|
|
457,951
|
|
|
402,997
|
|
|||
|
|
|
|
|
|
||||||
Gross profit
|
427,454
|
|
|
413,971
|
|
|
367,160
|
|
|||
|
|
|
|
|
|
||||||
Expenses:
|
|
|
|
|
|
|
|
|
|||
Selling
|
140,232
|
|
|
129,642
|
|
|
116,113
|
|
|||
General and administrative
|
172,383
|
|
|
138,019
|
|
|
122,270
|
|
|||
Research and development
|
31,320
|
|
|
24,646
|
|
|
18,367
|
|
|||
Total operating expenses
|
343,935
|
|
|
292,307
|
|
|
256,750
|
|
|||
|
|
|
|
|
|
||||||
Income from operations
|
83,519
|
|
|
121,664
|
|
|
110,410
|
|
|||
|
|
|
|
|
|
||||||
Interest expense, net
|
9,505
|
|
|
5,289
|
|
|
4,303
|
|
|||
Other income
|
(1,305
|
)
|
|
(1,138
|
)
|
|
(126
|
)
|
|||
|
|
|
|
|
|
||||||
Income before income taxes
|
75,319
|
|
|
117,513
|
|
|
106,233
|
|
|||
|
|
|
|
|
|
||||||
Income taxes
|
20,277
|
|
|
26,472
|
|
|
34,855
|
|
|||
|
|
|
|
|
|
||||||
Net income
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
|
|
|
|
|
|
||||||
Earnings per common share:
|
|
|
|
|
|
|
|
|
|||
Basic
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
Diluted
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
Dividends per common share
|
$
|
0.20
|
|
|
$
|
0.17
|
|
|
$
|
0.14
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Net income
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
|
|
|
|
|
|
||||||
Other comprehensive (loss) income:
|
|
|
|
|
|
||||||
Foreign currency translation
|
(13,287
|
)
|
|
(1,556
|
)
|
|
1,895
|
|
|||
Interest rate swap, net of tax
|
2,546
|
|
|
—
|
|
|
—
|
|
|||
Total other comprehensive (loss) income:
|
(10,741
|
)
|
|
(1,556
|
)
|
|
1,895
|
|
|||
|
|
|
|
|
|
||||||
Comprehensive income
|
$
|
44,301
|
|
|
$
|
89,485
|
|
|
$
|
73,273
|
|
|
|
|
Additional Paid-in Capital
|
|
Retained Earnings
|
|
Accumulated Other Comprehensive Loss
|
|
Treasury
Stock,
at cost
|
|
Total Stockholders’ Equity
|
|||||||||||||||
|
Common Stock
|
|
|
|
|
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|
||||||||||||||||||
Balance, August 1, 2016
|
41,708,214
|
|
|
$
|
4,608
|
|
|
$
|
165,573
|
|
|
$
|
342,053
|
|
|
$
|
(11,795
|
)
|
|
$
|
(46,069
|
)
|
|
$
|
454,370
|
|
Repurchases of shares
|
(89,607
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6,910
|
)
|
|
(6,910
|
)
|
||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
8,844
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8,844
|
|
||||||
Equity vests/option exercises
|
116,506
|
|
|
12
|
|
|
(12
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Cancellations of restricted stock
|
(6,179
|
)
|
|
(1
|
)
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Excess tax benefit from exercises of stock options and vesting of restricted stock
|
—
|
|
|
—
|
|
|
196
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
196
|
|
||||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,841
|
)
|
|
—
|
|
|
—
|
|
|
(5,841
|
)
|
||||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
71,378
|
|
|
—
|
|
|
—
|
|
|
71,378
|
|
||||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,895
|
|
|
—
|
|
|
1,895
|
|
||||||
Balance, July 31, 2017
|
41,728,934
|
|
|
$
|
4,619
|
|
|
$
|
174,602
|
|
|
$
|
407,590
|
|
|
$
|
(9,900
|
)
|
|
$
|
(52,979
|
)
|
|
$
|
523,932
|
|
Repurchases of shares
|
(62,559
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,074
|
)
|
|
(7,074
|
)
|
||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
9,615
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9,615
|
|
||||||
Equity vests/option exercises
|
46,551
|
|
|
5
|
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Cancellations of restricted stock
|
(6,842
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
—
|
|
|
(7,091
|
)
|
|
—
|
|
|
—
|
|
|
(7,091
|
)
|
||||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
91,041
|
|
|
—
|
|
|
—
|
|
|
91,041
|
|
||||||
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,556
|
)
|
|
—
|
|
|
(1,556
|
)
|
||||||
Balance, July 31, 2018
|
41,706,084
|
|
|
$
|
4,624
|
|
|
$
|
184,212
|
|
|
$
|
491,540
|
|
|
$
|
(11,456
|
)
|
|
$
|
(60,053
|
)
|
|
$
|
608,867
|
|
Repurchases of shares
|
(43,734
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,741
|
)
|
|
(4,741
|
)
|
||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
15,562
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
15,562
|
|
||||||
Issuance of shares
|
42,703
|
|
|
4
|
|
|
3,206
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,210
|
|
||||||
Equity vests/option exercises
|
67,862
|
|
|
8
|
|
|
942
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
950
|
|
||||||
Cancellations of restricted stock
|
(1,687
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Dividends on common stock
|
—
|
|
|
—
|
|
|
—
|
|
|
(8,350
|
)
|
|
—
|
|
|
—
|
|
|
(8,350
|
)
|
||||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
55,042
|
|
|
—
|
|
|
—
|
|
|
55,042
|
|
||||||
Cumulative impact of ASC 606 adoption
|
—
|
|
|
—
|
|
|
—
|
|
|
865
|
|
|
—
|
|
|
—
|
|
|
865
|
|
||||||
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(10,741
|
)
|
|
—
|
|
|
(10,741
|
)
|
||||||
Other
|
—
|
|
|
—
|
|
|
873
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
873
|
|
||||||
Balance, July 31, 2019
|
41,771,228
|
|
|
$
|
4,636
|
|
|
$
|
204,795
|
|
|
$
|
539,097
|
|
|
$
|
(22,197
|
)
|
|
$
|
(64,794
|
)
|
|
$
|
661,537
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|||
Net income
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|||
Depreciation
|
21,510
|
|
|
17,473
|
|
|
15,045
|
|
|||
Amortization
|
20,849
|
|
|
17,357
|
|
|
18,407
|
|
|||
Stock-based compensation expense
|
15,562
|
|
|
9,615
|
|
|
8,844
|
|
|||
Deferred income taxes
|
(2,062
|
)
|
|
(7,520
|
)
|
|
118
|
|
|||
Other non-cash items, net
|
(1,940
|
)
|
|
1,076
|
|
|
1,102
|
|
|||
Changes in assets and liabilities, net of effects of business acquisitions/divestitures:
|
|
|
|
|
|
|
|
|
|||
Accounts receivable
|
(23,048
|
)
|
|
(3,700
|
)
|
|
(12,860
|
)
|
|||
Inventories
|
(28,711
|
)
|
|
(3,785
|
)
|
|
887
|
|
|||
Prepaid expenses and other assets
|
(2,364
|
)
|
|
(5,169
|
)
|
|
(957
|
)
|
|||
Accounts payable and other liabilities
|
13,325
|
|
|
10,614
|
|
|
7,124
|
|
|||
Income taxes
|
(1,232
|
)
|
|
(1,090
|
)
|
|
(895
|
)
|
|||
Net cash provided by operating activities
|
66,931
|
|
|
125,912
|
|
|
108,193
|
|
|||
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
|||
Capital expenditures
|
(95,438
|
)
|
|
(37,698
|
)
|
|
(27,065
|
)
|
|||
Proceeds from disposal of fixed assets
|
—
|
|
|
—
|
|
|
47
|
|
|||
Proceeds from sale of business, net of cash retained and disposal costs
|
3,053
|
|
|
—
|
|
|
—
|
|
|||
Acquisition of businesses, net of cash acquired
|
(40,644
|
)
|
|
(87,488
|
)
|
|
(70,044
|
)
|
|||
Net cash used in investing activities
|
(133,029
|
)
|
|
(125,186
|
)
|
|
(97,062
|
)
|
|||
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
|||
Proceeds from issuance of long-term debt
|
—
|
|
|
200,000
|
|
|
—
|
|
|||
Repayments of long-term debt
|
(15,207
|
)
|
|
—
|
|
|
—
|
|
|||
Borrowings under revolving credit facility
|
50,000
|
|
|
82,300
|
|
|
74,000
|
|
|||
Repayments under revolving credit facility
|
(7,000
|
)
|
|
(208,300
|
)
|
|
(64,000
|
)
|
|||
Debt issuance costs
|
—
|
|
|
(2,698
|
)
|
|
—
|
|
|||
Dividends paid
|
(8,350
|
)
|
|
(7,091
|
)
|
|
(5,841
|
)
|
|||
Purchases of treasury stock
|
(4,741
|
)
|
|
(7,074
|
)
|
|
(6,910
|
)
|
|||
Net cash provided by (used in) financing activities
|
14,702
|
|
|
57,137
|
|
|
(2,751
|
)
|
|||
Effect of exchange rate changes on cash and cash equivalents
|
1,834
|
|
|
(350
|
)
|
|
(163
|
)
|
|||
(Decrease) increase in cash and cash equivalents
|
(49,562
|
)
|
|
57,513
|
|
|
8,217
|
|
|||
Cash and cash equivalents at beginning of period
|
94,097
|
|
|
36,584
|
|
|
28,367
|
|
|||
Cash and cash equivalents at end of period
|
$
|
44,535
|
|
|
$
|
94,097
|
|
|
$
|
36,584
|
|
|
|
|
|
|
|
||||||
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
||||||
Cash interest payments
|
$
|
9,296
|
|
|
$
|
5,156
|
|
|
$
|
3,455
|
|
Cash income tax payments
|
$
|
19,024
|
|
|
$
|
35,251
|
|
|
$
|
35,858
|
|
Accruals related to purchases of property and equipment
|
$
|
3,311
|
|
|
$
|
2,281
|
|
|
$
|
192
|
|
1.
|
Business Description
|
2.
|
Summary of Significant Accounting Policies
|
|
Year Ended July 31,
|
||||||
Net sales by geography
|
2019
|
|
2018(1)
|
||||
United States
|
$
|
665,661
|
|
|
$
|
643,744
|
|
Europe/Africa/Middle East
|
148,334
|
|
|
131,130
|
|
||
Asia/Pacific
|
66,228
|
|
|
57,108
|
|
||
Canada
|
32,152
|
|
|
33,524
|
|
||
Latin America/South America
|
5,780
|
|
|
6,416
|
|
||
Total
|
$
|
918,155
|
|
|
$
|
871,922
|
|
Net sales by product line
|
|
|
|
||||
Capital equipment
|
$
|
221,668
|
|
|
$
|
240,153
|
|
Consumables
|
569,412
|
|
|
523,073
|
|
||
Product service
|
122,752
|
|
|
106,764
|
|
||
All other(2)
|
4,323
|
|
|
1,932
|
|
||
Total
|
$
|
918,155
|
|
|
$
|
871,922
|
|
(1)
|
As noted above, prior year amounts have not been adjusted under the modified retrospective method.
|
(2)
|
Primarily includes software licensing revenues.
|
|
Contract Liabilities
|
||
Balance, August 1, 2018
|
$
|
29,015
|
|
Revenue deferred in current year
|
61,996
|
|
|
Deferred revenue recognized
|
(61,913
|
)
|
|
Foreign currency translation
|
(863
|
)
|
|
Balance, July 31, 2019
|
$
|
28,235
|
|
Contract liabilities included in Other long-term liabilities
|
(395
|
)
|
|
Deferred revenue
|
$
|
27,840
|
|
4.
|
Acquisitions
|
|
|
2019
|
|
2018
|
||||||||||||
Purchase Price Allocation
|
|
Omnia
|
|
CES Business(1)
|
|
Aexis
|
|
BHT Group
|
||||||||
|
|
(Preliminary)
|
|
(Preliminary)
|
|
(Final)
|
|
(Final)
|
||||||||
Purchase Price:
|
|
|
|
|
|
|
|
|
||||||||
Cash paid
|
|
$
|
16,598
|
|
|
$
|
17,047
|
|
|
$
|
20,308
|
|
|
$
|
60,216
|
|
Fair value of contingent consideration
|
|
—
|
|
|
—
|
|
|
1,292
|
|
|
—
|
|
||||
Common stock issued
|
|
3,210
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Total
|
|
$
|
19,808
|
|
|
$
|
17,047
|
|
|
$
|
21,600
|
|
|
$
|
60,216
|
|
|
|
|
|
|
|
|
|
|
||||||||
Allocation:
|
|
|
|
|
|
|
|
|
||||||||
Property and equipment
|
|
1,285
|
|
|
539
|
|
|
130
|
|
|
835
|
|
||||
Amortizable intangible assets:
|
|
|
|
|
|
|
|
|
||||||||
Customer relationships
|
|
10,206
|
|
|
8,100
|
|
|
1,800
|
|
|
12,500
|
|
||||
Technology
|
|
1,257
|
|
|
—
|
|
|
4,600
|
|
|
6,200
|
|
||||
Brand names
|
|
1,600
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Goodwill
|
|
11,340
|
|
|
6,137
|
|
|
17,092
|
|
|
40,934
|
|
||||
Deferred income taxes
|
|
(2,346
|
)
|
|
—
|
|
|
(1,639
|
)
|
|
(5,881
|
)
|
||||
Other working capital
|
|
1,673
|
|
|
2,271
|
|
|
909
|
|
|
5,628
|
|
||||
Contingent consideration
|
|
—
|
|
|
—
|
|
|
(1,292
|
)
|
|
—
|
|
||||
Long-term debt
|
|
(5,207
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Total
|
|
$
|
19,808
|
|
|
$
|
17,047
|
|
|
$
|
21,600
|
|
|
$
|
60,216
|
|
(1)
|
The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Raw materials and parts
|
$
|
69,498
|
|
|
$
|
49,054
|
|
Work-in-process
|
5,801
|
|
|
13,189
|
|
||
Finished goods
|
73,050
|
|
|
53,948
|
|
||
Less: reserve for excess and obsolete inventory
|
(10,115
|
)
|
|
(8,599
|
)
|
||
Total inventories, net
|
$
|
138,234
|
|
|
$
|
107,592
|
|
6.
|
Property and Equipment, Net
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Land, buildings and improvements
|
$
|
81,556
|
|
|
$
|
50,162
|
|
Furniture and equipment
|
130,852
|
|
|
112,661
|
|
||
Leasehold improvements
|
14,428
|
|
|
9,544
|
|
||
Software
|
33,869
|
|
|
8,587
|
|
||
Construction in process
|
38,728
|
|
|
26,003
|
|
||
Less: accumulated depreciation
|
(114,191
|
)
|
|
(95,540
|
)
|
||
Total property and equipment, net
|
$
|
185,242
|
|
|
$
|
111,417
|
|
7.
|
Derivatives
|
8.
|
Fair Value Measurements
|
|
July 31, 2019
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money markets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Prepaid expenses and other current assets:
|
|
|
|
|
|
|
|
||||||||
Interest rate swap
|
—
|
|
|
486
|
|
|
—
|
|
|
486
|
|
||||
Other Assets:
|
|
|
|
|
|
|
|
||||||||
Interest rate swap
|
—
|
|
|
2,826
|
|
|
—
|
|
|
2,826
|
|
||||
Total assets
|
$
|
104
|
|
|
$
|
3,312
|
|
|
$
|
—
|
|
|
$
|
3,416
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other long-term liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Contingent consideration
|
—
|
|
|
—
|
|
|
1,411
|
|
|
1,411
|
|
||||
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,411
|
|
|
$
|
1,411
|
|
|
July 31, 2018
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money markets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Total assets
|
$
|
104
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
104
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other long-term liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Contingent consideration
|
—
|
|
|
—
|
|
|
1,298
|
|
|
1,298
|
|
||||
Total liabilities
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,298
|
|
|
$
|
1,298
|
|
|
Aexis Medical Contingent Consideration
|
|
Jet Prep Assumed Contingent Obligation
|
|
Cantel Medical (U.K.) Contingent Guaranteed Obligation
|
|
Total
|
||||||||
Balance, August 1, 2016
|
$
|
—
|
|
|
$
|
1,138
|
|
|
$
|
441
|
|
|
$
|
1,579
|
|
Income included in general and administrative expenses
|
—
|
|
|
—
|
|
|
(265
|
)
|
|
(265
|
)
|
||||
Net purchases, issuances, sales and settlements
|
—
|
|
|
—
|
|
|
(176
|
)
|
|
(176
|
)
|
||||
Balance, July 31, 2017
|
—
|
|
|
1,138
|
|
|
—
|
|
|
1,138
|
|
||||
Original fair value of contingent consideration
|
1,292
|
|
|
—
|
|
|
—
|
|
|
1,292
|
|
||||
Loss included in general and administrative expenses
|
6
|
|
|
—
|
|
|
—
|
|
|
6
|
|
||||
Net purchases, issuances, sales and settlements
|
—
|
|
|
(1,138
|
)
|
|
—
|
|
|
(1,138
|
)
|
||||
Balance, July 31, 2018
|
1,298
|
|
|
—
|
|
|
—
|
|
|
1,298
|
|
||||
Loss included in general and administrative expense
|
113
|
|
|
—
|
|
|
—
|
|
|
113
|
|
||||
Balance, July 31, 2019
|
$
|
1,411
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,411
|
|
9.
|
Intangibles and Goodwill
|
|
July 31, 2019
|
|
July 31, 2018
|
||||||||||||||||||||
|
Gross
|
|
Accumulated Amortization
|
|
Net
|
|
Gross
|
|
Accumulated Amortization
|
|
Net
|
||||||||||||
Intangible assets with finite lives(1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Customer relationships(2)
|
$
|
146,204
|
|
|
$
|
(54,866
|
)
|
|
$
|
91,338
|
|
|
$
|
133,347
|
|
|
$
|
(45,618
|
)
|
|
$
|
87,729
|
|
Technology(3)
|
60,032
|
|
|
(24,081
|
)
|
|
35,951
|
|
|
54,585
|
|
|
(19,836
|
)
|
|
34,749
|
|
||||||
Brand names(2)
|
8,361
|
|
|
(3,256
|
)
|
|
5,105
|
|
|
8,141
|
|
|
(3,857
|
)
|
|
4,284
|
|
||||||
Non-compete agreements(4)
|
2,880
|
|
|
(1,653
|
)
|
|
1,227
|
|
|
3,060
|
|
|
(1,628
|
)
|
|
1,432
|
|
||||||
Patents and other registrations(5)
|
2,866
|
|
|
(1,252
|
)
|
|
1,614
|
|
|
2,826
|
|
|
(1,179
|
)
|
|
1,647
|
|
||||||
|
220,343
|
|
|
(85,108
|
)
|
|
135,235
|
|
|
201,959
|
|
|
(72,118
|
)
|
|
129,841
|
|
||||||
Trademarks and tradenames
|
6,278
|
|
|
—
|
|
|
6,278
|
|
|
7,520
|
|
|
—
|
|
|
7,520
|
|
||||||
Total intangible assets
|
$
|
226,621
|
|
|
$
|
(85,108
|
)
|
|
$
|
141,513
|
|
|
$
|
209,479
|
|
|
$
|
(72,118
|
)
|
|
$
|
137,361
|
|
(1)
|
During fiscal 2019, we wrote off $6,087 of fully amortized intangible assets.
|
(2)
|
Weighted average amortization period remaining of 13 years.
|
(3)
|
Weighted average amortization period remaining of 10 years.
|
(4)
|
Weighted average amortization period remaining of 15 years.
|
(5)
|
Weighted average amortization period remaining of 18 years.
|
|
Medical
|
|
Life Sciences
|
|
Dental
|
|
Dialysis
|
|
Total
Goodwill
|
||||||||||
Balance, August 1, 2017
|
$
|
129,945
|
|
|
$
|
59,088
|
|
|
$
|
114,279
|
|
|
$
|
8,133
|
|
|
$
|
311,445
|
|
Acquisitions
|
58,026
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
58,026
|
|
|||||
Foreign currency translation
|
(1,281
|
)
|
|
(163
|
)
|
|
—
|
|
|
—
|
|
|
(1,444
|
)
|
|||||
Balance, July 31, 2018
|
186,690
|
|
|
58,925
|
|
|
114,279
|
|
|
8,133
|
|
|
368,027
|
|
|||||
Acquisitions
|
—
|
|
|
6,137
|
|
|
11,340
|
|
|
—
|
|
|
17,477
|
|
|||||
Divestitures
|
—
|
|
|
(491
|
)
|
|
—
|
|
|
—
|
|
|
(491
|
)
|
|||||
Foreign currency translation
|
(6,493
|
)
|
|
(90
|
)
|
|
(321
|
)
|
|
—
|
|
|
(6,904
|
)
|
|||||
Balance, July 31, 2019
|
$
|
180,197
|
|
|
$
|
64,481
|
|
|
$
|
125,298
|
|
|
$
|
8,133
|
|
|
$
|
378,109
|
|
10.
|
Financing Arrangements
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Revolving credit loans outstanding
|
$
|
43,000
|
|
|
$
|
—
|
|
Tranche A term loan outstanding
|
190,000
|
|
|
200,000
|
|
||
Unamortized debt issuance costs
|
(2,149
|
)
|
|
(2,698
|
)
|
||
Total long-term debt, net of unamortized debt issuance costs
|
230,851
|
|
|
197,302
|
|
||
Current portion of long-term debt
|
(10,000
|
)
|
|
(10,000
|
)
|
||
Long-term debt, net of unamortized debt issuance costs and excluding current portion
|
$
|
220,851
|
|
|
$
|
187,302
|
|
11.
|
Income Taxes
|
|
Year Ended July 31,
|
||||||||||||||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||||||||||||||
|
Current
|
|
Deferred
|
|
Current
|
|
Deferred
|
|
Current
|
|
Deferred
|
||||||||||||
United States:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Federal
|
$
|
13,494
|
|
|
$
|
683
|
|
|
$
|
24,288
|
|
|
$
|
(7,308
|
)
|
|
$
|
28,900
|
|
|
$
|
2,020
|
|
State
|
3,976
|
|
|
(15
|
)
|
|
5,078
|
|
|
491
|
|
|
4,352
|
|
|
261
|
|
||||||
International
|
4,869
|
|
|
(2,730
|
)
|
|
4,626
|
|
|
(703
|
)
|
|
1,545
|
|
|
(2,223
|
)
|
||||||
Total
|
$
|
22,339
|
|
|
$
|
(2,062
|
)
|
|
$
|
33,992
|
|
|
$
|
(7,520
|
)
|
|
$
|
34,797
|
|
|
$
|
58
|
|
|
Year Ended July 31,
|
|||||||
|
2019
|
|
2018
|
|
2017
|
|||
Expected statutory tax(1)
|
21.0
|
%
|
|
26.9
|
%
|
|
35.0
|
%
|
Differential attributable to:
|
|
|
|
|
|
|
|
|
Foreign operations
|
0.8
|
%
|
|
0.6
|
%
|
|
—
|
%
|
State and local taxes
|
4.8
|
%
|
|
3.7
|
%
|
|
3.9
|
%
|
Domestic production deduction
|
—
|
%
|
|
(1.8
|
)%
|
|
(2.7
|
)%
|
Acquisition-related items, net
|
0.1
|
%
|
|
—
|
%
|
|
0.1
|
%
|
Impact of tax legislation on deferred taxes
|
(0.1
|
)%
|
|
(7.4
|
)%
|
|
—
|
%
|
R&E tax credit
|
(1.0
|
)%
|
|
(0.7
|
)%
|
|
(1.4
|
)%
|
Executive compensation
|
1.4
|
%
|
|
0.2
|
%
|
|
0.3
|
%
|
Excess tax benefits
|
(0.7
|
)%
|
|
(1.7
|
)%
|
|
(2.2
|
)%
|
Valuation allowance
|
0.1
|
%
|
|
2.4
|
%
|
|
—
|
%
|
Other
|
0.5
|
%
|
|
0.3
|
%
|
|
(0.2
|
)%
|
Consolidated effective income tax rate
|
26.9
|
%
|
|
22.5
|
%
|
|
32.8
|
%
|
(1)
|
During fiscal 2018, we revised our estimated annual rate to reflect a blended U.S. federal statutory rate of 26.9% as compared to 35.0%.
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Deferred tax assets:
|
|
|
|
|
|
||
Accrued expenses
|
$
|
4,175
|
|
|
$
|
5,354
|
|
Inventories
|
5,408
|
|
|
3,165
|
|
||
Accounts receivable
|
593
|
|
|
306
|
|
||
Other long-term liabilities
|
211
|
|
|
103
|
|
||
Stock-based compensation
|
3,586
|
|
|
2,700
|
|
||
Capital investment
|
426
|
|
|
426
|
|
||
Domestic NOLs
|
137
|
|
|
—
|
|
||
Foreign NOLs
|
10,284
|
|
|
8,605
|
|
||
Subtotal
|
24,820
|
|
|
20,659
|
|
||
Valuation allowance
|
(5,701
|
)
|
|
(6,358
|
)
|
||
|
19,119
|
|
|
14,301
|
|
||
Deferred tax liabilities:
|
|
|
|
|
|
||
Property and equipment
|
(11,342
|
)
|
|
(7,352
|
)
|
||
Intangible assets
|
(21,156
|
)
|
|
(21,300
|
)
|
||
Goodwill
|
(11,618
|
)
|
|
(10,362
|
)
|
||
|
(44,116
|
)
|
|
(39,014
|
)
|
||
Net deferred income taxes
|
$
|
(24,997
|
)
|
|
$
|
(24,713
|
)
|
|
|
|
|
||||
Reported in Consolidated Balance Sheets as:
|
|
|
|
||||
Deferred income taxes (assets)
|
$
|
4,281
|
|
|
$
|
2,911
|
|
Deferred income taxes (liabilities)
|
(29,278
|
)
|
|
(27,624
|
)
|
||
|
$
|
(24,997
|
)
|
|
$
|
(24,713
|
)
|
Fiscal year ending:
|
Total
|
||
2020
|
$
|
9,099
|
|
2021
|
7,671
|
|
|
2022
|
6,021
|
|
|
2023
|
5,659
|
|
|
2024
|
5,159
|
|
|
Thereafter
|
15,251
|
|
|
Total
|
$
|
48,860
|
|
13.
|
Accumulated Other Comprehensive Loss
|
|
Foreign Currency Translation Adjustments
|
|
Changes in Fair Value of Interest Rate Swaps
|
|
Tax effects
|
|
Total
|
||||||||
Balance, August 1, 2016
|
$
|
(11,795
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(11,795
|
)
|
Other comprehensive income
|
1,895
|
|
|
—
|
|
|
—
|
|
|
1,895
|
|
||||
Balance, July 31, 2017
|
(9,900
|
)
|
|
—
|
|
|
—
|
|
|
(9,900
|
)
|
||||
Other comprehensive loss
|
(1,556
|
)
|
|
—
|
|
|
—
|
|
|
(1,556
|
)
|
||||
Balance, July 31, 2018
|
(11,456
|
)
|
|
—
|
|
|
—
|
|
|
(11,456
|
)
|
||||
Other comprehensive (loss) income
|
(13,287
|
)
|
|
3,312
|
|
|
(766
|
)
|
|
(10,741
|
)
|
||||
Balance, July 31, 2019
|
$
|
(24,743
|
)
|
|
$
|
3,312
|
|
|
$
|
(766
|
)
|
|
$
|
(22,197
|
)
|
14.
|
Earnings Per Common Share
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Numerator for basic and diluted earnings per share:
|
|
|
|
|
|
|
|
|
|||
Net income
|
$
|
55,042
|
|
|
$
|
91,041
|
|
|
$
|
71,378
|
|
Less income allocated to participating securities
|
(51
|
)
|
|
(320
|
)
|
|
(431
|
)
|
|||
Net income available to common shareholders
|
$
|
54,991
|
|
|
$
|
90,721
|
|
|
$
|
70,947
|
|
Denominator for basic and diluted earnings per share, as adjusted for participating securities:
|
|
|
|
|
|
|
|
|
|||
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock
|
41,700,926
|
|
|
41,567,722
|
|
|
41,468,487
|
|
|||
Dilutive effect of stock options using the treasury stock method and the average market price for the year
|
56,190
|
|
|
67,356
|
|
|
74,278
|
|
|||
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock
|
41,757,116
|
|
|
41,635,078
|
|
|
41,542,765
|
|
|||
Earnings per share attributable to common stock:
|
|
|
|
|
|
|
|
|
|||
Basic earnings per share
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
Diluted earnings per share
|
$
|
1.32
|
|
|
$
|
2.18
|
|
|
$
|
1.71
|
|
Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive
|
—
|
|
|
—
|
|
|
—
|
|
|
Year Ended July 31,
|
|||||||
|
2019
|
|
2018
|
|
2017
|
|||
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock
|
41,757,116
|
|
|
41,635,078
|
|
|
41,542,765
|
|
Participating securities
|
38,905
|
|
|
148,700
|
|
|
254,727
|
|
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities
|
41,796,021
|
|
|
41,783,778
|
|
|
41,797,492
|
|
15.
|
Stock-Based Compensation
|
•
|
will be granted at the closing market price at the time of the grant,
|
•
|
will include terms which may not exceed ten years, subject to certain exceptions, and
|
•
|
may be granted in the form of restricted stock and RSUs, performance awards, or dividends.
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Cost of sales
|
$
|
1,010
|
|
|
$
|
663
|
|
|
$
|
371
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|||
Selling
|
2,428
|
|
|
1,458
|
|
|
1,582
|
|
|||
General and administrative
|
11,828
|
|
|
7,292
|
|
|
6,774
|
|
|||
Research and development
|
296
|
|
|
202
|
|
|
117
|
|
|||
Total operating expenses
|
14,552
|
|
|
8,952
|
|
|
8,473
|
|
|||
Stock-based compensation before income taxes
|
$
|
15,562
|
|
|
$
|
9,615
|
|
|
$
|
8,844
|
|
|
|
2019
|
|
2018
|
||
Volatility of common stock
|
|
27.54
|
%
|
|
26.60
|
%
|
Average volatility of peer companies
|
|
36.55
|
%
|
|
33.72
|
%
|
Average correlation coefficient of peer companies
|
|
27.18
|
%
|
|
32.26
|
%
|
Risk-free interest rate
|
|
2.93
|
%
|
|
1.62
|
%
|
|
|
Number of Time-based Shares
|
|
Number of Performance-based Shares
|
|
Number of Market-based Shares
|
|
Number of Total Shares
|
|
Weighted Average Fair Value
|
||||||
August 1, 2016
|
|
331,367
|
|
|
—
|
|
|
—
|
|
|
331,367
|
|
|
$
|
46.09
|
|
Granted
|
|
86,305
|
|
|
16,960
|
|
|
9,800
|
|
|
113,065
|
|
|
$
|
81.77
|
|
Vested(1)
|
|
(214,932
|
)
|
|
(725
|
)
|
|
(555
|
)
|
|
(216,212
|
)
|
|
$
|
43.62
|
|
Forfeited
|
|
(5,922
|
)
|
|
—
|
|
|
—
|
|
|
(5,922
|
)
|
|
$
|
59.40
|
|
July 31, 2017
|
|
196,818
|
|
|
16,235
|
|
|
9,245
|
|
|
222,298
|
|
|
$
|
66.28
|
|
Granted
|
|
94,309
|
|
|
17,486
|
|
|
10,465
|
|
|
122,260
|
|
|
$
|
101.74
|
|
Vested(1)
|
|
(115,943
|
)
|
|
(5,845
|
)
|
|
—
|
|
|
(121,788
|
)
|
|
$
|
60.25
|
|
Forfeited
|
|
(6,864
|
)
|
|
(1,800
|
)
|
|
(2,000
|
)
|
|
(10,664
|
)
|
|
$
|
95.09
|
|
July 31, 2018
|
|
168,320
|
|
|
26,076
|
|
|
17,710
|
|
|
212,106
|
|
|
$
|
88.87
|
|
Granted
|
|
188,431
|
|
|
35,981
|
|
|
25,320
|
|
|
249,732
|
|
|
$
|
85.16
|
|
Vested(1)
|
|
(105,516
|
)
|
|
(13,327
|
)
|
|
(5,265
|
)
|
|
(124,108
|
)
|
|
$
|
80.44
|
|
Forfeited
|
|
(16,371
|
)
|
|
(8,520
|
)
|
|
(5,686
|
)
|
|
(30,577
|
)
|
|
$
|
96.54
|
|
July 31, 2019
|
|
234,864
|
|
|
40,210
|
|
|
32,079
|
|
|
307,153
|
|
|
$
|
88.99
|
|
(1)
|
The aggregate fair value of all nonvested stock awards which vested was approximately $9,985, $7,338 and $9,431 in fiscal 2019, 2018 and 2017, respectively.
|
|
Number of shares
|
|
Weighted Average Exercise Price
|
|
Weighted Average Contractual Life Remaining
|
|
Aggregate Intrinsic Value
|
|||||
Outstanding at August 1, 2016
|
122,500
|
|
|
$
|
29.36
|
|
|
|
|
|
||
Exercised
|
—
|
|
|
$
|
—
|
|
|
|
|
|
||
Outstanding at July 31, 2017
|
122,500
|
|
|
$
|
29.36
|
|
|
|
|
|
||
Exercised
|
(52,500
|
)
|
|
$
|
17.04
|
|
|
|
|
|
||
Outstanding at July 31, 2018
|
70,000
|
|
|
$
|
38.60
|
|
|
|
|
|
||
Exercised
|
(30,000
|
)
|
|
$
|
31.81
|
|
|
|
|
|
||
Outstanding at July 31, 2019
|
40,000
|
|
|
$
|
43.70
|
|
|
0.57 years
|
|
$
|
1,943
|
|
Exercisable at July 31, 2019
|
40,000
|
|
|
$
|
43.70
|
|
|
0.57 years
|
|
$
|
1,943
|
|
16.
|
Retirement Plans
|
17.
|
Reportable Segments
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Net sales:
|
|
|
|
|
|
|
|
|
|||
Medical
|
$
|
523,669
|
|
|
$
|
473,937
|
|
|
$
|
398,773
|
|
Life Sciences (1)
|
201,022
|
|
|
217,030
|
|
|
196,446
|
|
|||
Dental (1)
|
161,608
|
|
|
149,360
|
|
|
144,457
|
|
|||
Dialysis
|
31,856
|
|
|
31,595
|
|
|
30,481
|
|
|||
Total
|
$
|
918,155
|
|
|
$
|
871,922
|
|
|
$
|
770,157
|
|
(1)
|
In fiscal 2018, approximately $5,820 of net sales were reclassified out of our Dental segment and into our Life Sciences segment associated with the changes in our segments noted above. Fiscal 2017 amounts were not material and were not adjusted.
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Income from operations:
|
|
|
|
|
|
|
|
|
|||
Medical
|
$
|
98,356
|
|
|
$
|
86,833
|
|
|
$
|
73,440
|
|
Life Sciences (1)
|
20,552
|
|
|
36,803
|
|
|
33,159
|
|
|||
Dental (1)
|
22,289
|
|
|
30,004
|
|
|
28,000
|
|
|||
Dialysis
|
4,922
|
|
|
7,380
|
|
|
8,154
|
|
|||
|
146,119
|
|
|
161,020
|
|
|
142,753
|
|
|||
General corporate expenses
|
62,600
|
|
|
39,356
|
|
|
32,343
|
|
|||
Income from operations
|
83,519
|
|
|
121,664
|
|
|
110,410
|
|
|||
Interest expense, net
|
9,505
|
|
|
5,289
|
|
|
4,303
|
|
|||
Other income
|
(1,305
|
)
|
|
(1,138
|
)
|
|
(126
|
)
|
|||
Income before income taxes
|
$
|
75,319
|
|
|
$
|
117,513
|
|
|
$
|
106,233
|
|
(1)
|
In fiscal 2018, approximately $1,704 of income from operations were reclassified out of our Dental segment and into our Life Sciences segment associated with the changes in our segments noted above. Fiscal 2017 amounts were not material and were not adjusted.
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Identifiable assets:
|
|
|
|
|
|
||
Medical
|
$
|
532,250
|
|
|
$
|
490,702
|
|
Life Sciences
|
184,737
|
|
|
151,460
|
|
||
Dental
|
272,309
|
|
|
210,831
|
|
||
Dialysis
|
19,016
|
|
|
22,614
|
|
||
General corporate, including cash and cash equivalents
|
62,054
|
|
|
88,101
|
|
||
Total
|
$
|
1,070,366
|
|
|
$
|
963,708
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Capital expenditures:
|
|
|
|
|
|
|
|
|
|||
Medical
|
$
|
52,907
|
|
|
$
|
18,996
|
|
|
$
|
13,816
|
|
Life Sciences
|
16,408
|
|
|
4,409
|
|
|
3,689
|
|
|||
Dental
|
16,243
|
|
|
2,441
|
|
|
2,492
|
|
|||
Dialysis
|
3,203
|
|
|
644
|
|
|
1,296
|
|
|||
General corporate
|
6,677
|
|
|
11,208
|
|
|
5,772
|
|
|||
Total
|
$
|
95,438
|
|
|
37,698
|
|
|
27,065
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
|||
Medical
|
$
|
23,033
|
|
|
$
|
19,002
|
|
|
$
|
18,245
|
|
Life Sciences
|
7,482
|
|
|
5,628
|
|
|
5,706
|
|
|||
Dental
|
9,844
|
|
|
8,756
|
|
|
8,556
|
|
|||
Dialysis
|
39
|
|
|
711
|
|
|
427
|
|
|||
General corporate
|
1,961
|
|
|
733
|
|
|
518
|
|
|||
Total
|
$
|
42,359
|
|
|
$
|
34,830
|
|
|
$
|
33,452
|
|
|
Year Ended July 31,
|
||||||||||
|
2019
|
|
2018
|
|
2017
|
||||||
Net sales:
|
|
|
|
|
|
|
|
|
|||
United States
|
$
|
665,661
|
|
|
$
|
643,744
|
|
|
$
|
599,657
|
|
Europe/Africa/Middle East
|
148,334
|
|
|
131,130
|
|
|
95,753
|
|
|||
Asia/Pacific
|
66,228
|
|
|
57,108
|
|
|
40,964
|
|
|||
Canada
|
32,152
|
|
|
33,524
|
|
|
26,648
|
|
|||
Latin America/South America
|
5,780
|
|
|
6,416
|
|
|
7,135
|
|
|||
Total
|
$
|
918,155
|
|
|
$
|
871,922
|
|
|
$
|
770,157
|
|
|
July 31,
|
||||||
|
2019
|
|
2018
|
||||
Total long-lived assets:
|
|
|
|
|
|
||
United States
|
$
|
128,010
|
|
|
$
|
80,918
|
|
Europe/Africa/Middle East
|
64,742
|
|
|
35,824
|
|
||
Asia/Pacific
|
4,201
|
|
|
2,531
|
|
||
Canada
|
1,995
|
|
|
804
|
|
||
Total
|
198,948
|
|
|
120,077
|
|
||
Goodwill and intangible assets, net
|
519,622
|
|
|
505,388
|
|
||
Total
|
$
|
718,570
|
|
|
$
|
625,465
|
|
18.
|
Quarterly Results of Operations (unaudited)
|
Fiscal 2019
|
First Quarter
|
|
Second Quarter
|
|
Third Quarter
|
|
Fourth Quarter
|
||||||||
Net sales
|
$
|
225,589
|
|
|
$
|
224,538
|
|
|
$
|
228,552
|
|
|
$
|
239,476
|
|
Cost of sales
|
120,340
|
|
|
119,863
|
|
|
121,675
|
|
|
128,823
|
|
||||
Gross profit
|
105,249
|
|
|
104,675
|
|
|
106,877
|
|
|
110,653
|
|
||||
Gross profit percentage
|
46.7
|
%
|
|
46.6
|
%
|
|
46.8
|
%
|
|
46.2
|
%
|
||||
Net income
|
$
|
19,242
|
|
|
$
|
18,800
|
|
|
$
|
8,175
|
|
|
$
|
8,825
|
|
Earnings per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
$
|
0.46
|
|
|
$
|
0.45
|
|
|
$
|
0.20
|
|
|
$
|
0.21
|
|
Diluted
|
$
|
0.46
|
|
|
$
|
0.45
|
|
|
$
|
0.20
|
|
|
$
|
0.21
|
|
Fiscal 2018
|
First Quarter
|
|
Second Quarter
|
|
Third Quarter
|
|
Fourth Quarter
|
||||||||
Net sales
|
$
|
212,766
|
|
|
$
|
213,034
|
|
|
$
|
217,268
|
|
|
$
|
228,854
|
|
Cost of sales
|
112,107
|
|
|
111,799
|
|
|
112,594
|
|
|
121,451
|
|
||||
Gross profit
|
100,659
|
|
|
101,235
|
|
|
104,674
|
|
|
107,403
|
|
||||
Gross profit percentage
|
47.3
|
%
|
|
47.5
|
%
|
|
48.2
|
%
|
|
46.9
|
%
|
||||
Net income
|
$
|
22,929
|
|
|
$
|
32,488
|
|
|
$
|
18,736
|
|
|
$
|
16,888
|
|
Earnings per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
$
|
0.55
|
|
|
$
|
0.78
|
|
|
$
|
0.45
|
|
|
$
|
0.41
|
|
Diluted
|
$
|
0.55
|
|
|
$
|
0.78
|
|
|
$
|
0.45
|
|
|
$
|
0.41
|
|
19.
|
Subsequent Events
|
|
|
Balance
at Beginning of Period
|
|
Additions
|
|
Deductions
|
|
Translation Adjustments
|
|
Balance
at End
of Period
|
||||||||||
Allowance for doubtful accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Year ended July 31, 2019
|
|
$
|
1,149
|
|
|
$
|
1,541
|
|
|
$
|
(336
|
)
|
|
$
|
(32
|
)
|
|
$
|
2,322
|
|
Year ended July 31, 2018
|
|
$
|
1,808
|
|
|
$
|
326
|
|
|
$
|
(977
|
)
|
|
$
|
(8
|
)
|
|
$
|
1,149
|
|
Year ended July 31, 2017
|
|
$
|
1,850
|
|
|
$
|
998
|
|
|
$
|
(1,056
|
)
|
|
$
|
16
|
|
|
$
|
1,808
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Reserve for excess and obsolete inventory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Year ended July 31, 2019
|
|
$
|
8,599
|
|
|
$
|
2,937
|
|
|
$
|
(1,218
|
)
|
|
$
|
(203
|
)
|
|
$
|
10,115
|
|
Year ended July 31, 2018
|
|
$
|
8,853
|
|
|
$
|
1,719
|
|
|
$
|
(1,862
|
)
|
|
$
|
(111
|
)
|
|
$
|
8,599
|
|
Year ended July 31, 2017
|
|
$
|
5,390
|
|
|
$
|
5,016
|
|
|
$
|
(1,580
|
)
|
|
$
|
27
|
|
|
$
|
8,853
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Deferred tax asset valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Year ended July 31, 2019
|
|
$
|
6,358
|
|
|
$
|
1,086
|
|
|
$
|
(1,891
|
)
|
|
$
|
148
|
|
|
$
|
5,701
|
|
Year ended July 31, 2018
|
|
$
|
2,984
|
|
|
$
|
3,538
|
|
|
$
|
(119
|
)
|
|
$
|
(45
|
)
|
|
$
|
6,358
|
|
Year ended July 31, 2017
|
|
$
|
2,334
|
|
|
$
|
615
|
|
|
$
|
—
|
|
|
$
|
35
|
|
|
$
|
2,984
|
|
(i)
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company,
|
(ii)
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company, and
|
(iii)
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
|
|
|
Number of securities to be issued
upon exercise of outstanding options
|
|
Weighted-average exercise price of outstanding options
|
|
Number of securities remaining available for future issuance
under compensation plans (excluding securities reflected in (a))
|
|
||||
Plan Category
|
|
(a)
|
|
(b)
|
|
(c)
|
|
||||
Equity compensation plans approved by security holders
|
|
40,000
|
|
|
$
|
43.70
|
|
|
755,429
|
|
(1)
|
Equity compensation plans not approved by security holders
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
Total
|
|
40,000
|
|
|
$
|
43.70
|
|
|
755,429
|
|
(1)
|
(1)
|
Collectively consists of stock option and SARs awards and restricted stock and performance awards available for grant under the plans.
|
(a)
|
The following documents are filed as part of this Annual Report on Form 10-K for the fiscal year ended July 31, 2019.
|
1.
|
Consolidated Financial Statements:
|
(i)
|
Report of Independent Registered Public Accounting Firm.
|
(ii)
|
Consolidated Balance Sheets as of July 31, 2019 and 2018.
|
(iii)
|
Consolidated Statements of Income for the years ended July 31, 2019, 2018 and 2017.
|
(iv)
|
Consolidated Statements of Comprehensive Income for the years ended July 31, 2019, 2018 and 2017.
|
(v)
|
Consolidated Statements of Changes in Stockholders’ Equity for the years ended July 31, 2019, 2018 and 2017.
|
(vi)
|
Consolidated Statements of Cash Flows for the years ended July 31, 2019, 2018 and 2017.
|
(vii)
|
Notes to Consolidated Financial Statements.
|
2.
|
Consolidated Financial Statement Schedules:
|
(i)
|
Schedule II - Valuation and Qualifying Accounts for the years ended July 31, 2019, 2018 and 2017.
|
3.
|
Exhibits:
|
|
CANTEL MEDICAL CORP.
|
||
|
|
||
Date: September 25, 2019
|
By:
|
/s/ George L. Fotiades
|
|
|
George L. Fotiades, President,
|
||
|
Chief Executive Officer
|
||
|
(Principal Executive Officer)
|
||
|
|
||
|
By:
|
/s/ Shaun M. Blakeman
|
|
|
Shaun M. Blakeman, Senior Vice President,
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial Officer)
|
||
|
|
||
|
By:
|
/s/ Brian R. Capone
|
|
|
Brian R. Capone, Senior Vice President,
|
||
|
Chief Accounting Officer
|
||
|
(Principal Accounting Officer)
|
/s/ Charles M. Diker
|
|
Date:
|
|
September 25, 2019
|
Charles M. Diker, Director and Chairman of the Board
|
|
|
|
|
|
|
|
|
|
/s/ Alan. R. Batkin
|
|
Date:
|
|
September 25, 2019
|
Alan R. Batkin, Lead Independent Director
|
|
|
|
|
|
|
|
|
|
/s/ Ann E. Berman
|
|
Date:
|
|
September 25, 2019
|
Ann E. Berman, Director
|
|
|
|
|
|
|
|
|
|
/s/ Mark N. Diker
|
|
Date:
|
|
September 25, 2019
|
Mark N. Diker, Director
|
|
|
|
|
|
|
|
|
|
/s/ Anthony B. Evnin
|
|
Date:
|
|
September 25, 2019
|
Anthony B. Evnin, Director
|
|
|
|
|
|
|
|
|
|
/s/ Laura L. Forese
|
|
Date:
|
|
September 25, 2019
|
Laura L. Forese, Director
|
|
|
|
|
|
|
|
|
|
/s/ George L. Fotiades
|
|
Date:
|
|
September 25, 2019
|
George L. Fotiades, Director, President and CEO
|
|
|
|
|
|
|
|
|
|
/s/ Ronnie Myers
|
|
Date
|
|
September 25, 2019
|
Ronnie Myers, Director
|
|
|
|
|
|
|
|
|
|
/s/ Peter J. Pronovost, M.D., Ph.D.
|
|
Date:
|
|
September 25, 2019
|
Peter J. Pronovost, M.D., Ph.D., Director
|
|
|
|
|
•
|
before that person became an interested stockholder, our Board of Directors approved the transaction in which the interested stockholder became an interested stockholder or approved the business combination;
|
•
|
upon consummation of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) stock held by directors who are also officers of our Company and by employee stock plans that do not provide employees with the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or
|
•
|
following the transaction in which that person became an interested stockholder, the business combination is approved by our Board of Directors and authorized at a meeting of stockholders by the affirmative vote of the holders of at least 66 2/3% of our outstanding voting stock not owned by the interested stockholder.
|
•
|
permit our Board of Directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares
|
•
|
provide that vacancies on our Board of Directors may be filled by a majority of our Board of Directors then in office, although less than a quorum;
|
•
|
provide that stockholders do not have the right to cumulative voting in the election of directors;
|
•
|
provide that special meetings of stockholders may only be called by a majority of our Board of Directors, and that only proposals included in the Company’s notice or otherwise brought before the meeting by or at the direction of our Board of Directors may be considered at such special meetings; and
|
•
|
provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on the Company’s behalf, any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or other employees to us or to our stockholders, any action asserting a claim arising pursuant to the DGCL, or any action asserting a claim governed by the internal affairs doctrine.
|
1.
|
ESTABLISHMENT AND PURPOSE OF PLAN
|
2.
|
DEFINITIONS AND CONSTRUCTION
|
3.
|
SEVERANCE BENEFITS FOR QUALIFYING TERMINATIONS
|
Participant Level
|
Formula
|
Tier I Participant
|
2.0 x Participant's annual Base Salary as of the Termination Date.
|
Tier II Participant
|
1.0 x Participant's annual Base Salary as of the Termination Date.
|
Tier III Participant
|
0.75 x Participant's annual Base Salary as of the Termination Date.
|
Participant Level
|
Formula
|
Tier I Participant
|
2.0 x Participant's annual Base Salary as of the Termination Date.
|
Tier II Participant
|
2.0 x Participant's annual Base Salary as of the Termination Date.
|
Tier III Participant
|
1.0 x Participant's annual Base Salary as of the Termination Date.
|
4.
|
NO CONTRACT OF EMPLOYMENT
|
5.
|
CONFLICT IN BENEFITS; NONCUMULATION OF BENEFITS
|
6.
|
ADMINISTRATION, TERMINATION, AND AMENDMENT OF PLAN
|
7.
|
CLAIMS FOR BENEFITS
|
8.
|
NOTICES
|
9.
|
CERTAIN FEDERAL TAX CONSIDERATIONS
|
10.
|
ADDITIONAL PROVISIONS
|
•
|
Final Pay. You will be paid your regular base salary through and including the Termination Date, as well as any accrued and unused PTO (which includes vacation and sick days, but not floating holidays) through such date, subject to applicable taxes and withholding.
|
•
|
Reimbursement of Expenses. Provided that you apply for reimbursement in accordance with the Company’s established reimbursement procedures (within the period required by such procedures but under no circumstances later than ninety (90) days after the Termination Date), the Company will pay you any reimbursements to which you are entitled under such procedures.
|
•
|
Benefits. Your medical and dental insurance benefits (to the extent applicable) will be continued through the last day of the month in which the Termination Date occurred. You will have the option to continue these benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for up to 18 months, or for such other period as provided by law, provided that you timely apply for COBRA and timely pay the required premiums for COBRA continuation coverage. Your COBRA period will begin on the first day of the first month following the month in which the Termination Date occurs. You will receive COBRA information from our COBRA administrator promptly following the Termination Date, which will include information regarding the date by which you must enroll and the premiums you would be required to pay if you want COBRA coverage. All other benefits, including, but not limited to, PTO, and holiday pay, end on the Termination Date.
|
•
|
Severance Payment: The Company will pay you a Severance Payment in a single lump sum of [*], being [*] times your annual Base Salary as of the Termination Date, in accordance with Section 3.1(a) of the Plan.
|
•
|
[INCLUDE ONLY IF APPLICABLE] Prior Year Bonus Payment: If your Termination Date is after the end of the last Fiscal Year) but before the Bonus for that year has been paid, the Company will pay you the amount determined under the terms of the applicable Bonus plan notwithstanding any provision of the Bonus plan that requires continued employment after the end of the immediately preceding annual Bonus period but subject to all other provisions of the Bonus plan, in accordance with Section 3.1(c) of the Plan.]
|
•
|
Pro-Rated Bonus Payment: The Company will pay you a pro rata portion of your FY2019 target Bonus, based on achievement of 100% of the applicable performance target for such year, in accordance with Section 3.1(d) of the Plan.
|
•
|
COBRA Severance Benefit: The Company will pay you in a lump sum an amount equal to the sum of the employer portion and the employee portion of the full monthly premium for your elected coverage under the Cantel group health plan (including medical and dental coverages) as in effect on the day prior to the Termination Date, for a period of [*] months (the "COBRA Severance Benefit"). The COBRA Severance Benefit will be calculated and paid in accordance with Section 3.1(e) of the Plan. Section 1 above describes the steps you must take if you want to have COBRA coverage; nonetheless, this COBRA severance benefit is independent of whether you elect COBRA coverage (or any other coverage).
|
•
|
LTI: The [*] unvested time-based restricted stock units (RSUs) of Cantel held by you on the Termination Date that are scheduled to vest on or before [*] will be deemed vested and no longer subject to forfeiture as of the Termination Date. Notwithstanding the foregoing or any provision in any applicable RSU agreement to the contrary, shares in settlement of the vested RSUs, including all dividend equivalents associated therewith, will be delivered or the cash equivalent paid, as applicable, as of the payment date provided for in the original grant of such RSUs. You acknowledge and agree that any and all other RSUs held by you on the Termination Date will be forfeited on the Termination Date, and you are not entitled to, and are not receiving, any additional equity awards or cash equivalents on or after the date of this Agreement
|
•
|
Outplacement Assistance. Following the Termination Date, you will be entitled, at the Company's cost, to outplacement services for a period not to exceed twelve (12) months. Such services will be provided by a firm selected by the Company and subject to the standard terms of their applicable outplacement program. You must notify the Company of your desire to utilize such services within twenty (20) days following the Termination Date and commence such services within sixty (60) days following the Termination Date.
|
•
|
I have not suffered any on-the-job injury for which I have not already filed a claim, and the end of my employment is not related to any such injury.
|
•
|
I do not have any pending lawsuits against the Company.
|
•
|
I have had adequate time to consider whether to sign this Confidential Separation Agreement and General Release.
|
•
|
I have read this Confidential Separation Agreement and General Release carefully.
|
•
|
I understand, accept and agree to all of the terms of this Confidential Separation Agreement and General Release.
|
•
|
I am knowingly and voluntarily releasing my claims as set forth in this Confidential Separation Agreement and General Release.
|
•
|
I have not, in signing this Confidential Separation Agreement and General Release, relied upon any representations or statements, written or oral, or explanations made by the Company except for those specifically set forth in this Confidential Separation Agreement and General Release and the Confidentiality Agreement.
|
•
|
I intend this Confidential Separation Agreement and General Release to be legally binding.
|
•
|
I have kept a full copy of this Confidential Separation Agreement and General Release for my records.
|
Cantel (Canada) Inc.
|
(Incorporated under the laws of Ontario, Canada)
|
Medivators Inc.
|
(Incorporated under the laws of Minnesota)
|
Medivators B.V.
|
(Incorporated under the laws of the Netherlands)
|
Cantel Medical Asia/Pacific Pte. Ltd.
|
(Incorporated under the laws of Singapore)
|
Mar Cor Purification, Inc.
|
(Incorporated under the laws of Pennsylvania)
|
Crosstex International, Inc.
|
(Incorporated under the laws of New York)
|
SPS Medical Supply Corp.
|
(Incorporated under the laws of New York)
|
Cantel Medical International LLC
|
(Organized under the laws of Delaware)
|
CMCI C.V.
|
(Incorporated under the laws of the Netherlands)
|
Cantel Medical International B.V.
|
(Incorporated under the laws of the Netherlands)
|
Cantel (Belgium) BVBA
|
(Incorporated under the laws of Belgium)
|
Cantel Medical (UK) Limited
|
(Incorporated under the laws of England and Wales)
|
Cantel Lanka (Pvt) Ltd.
|
(Incorporated under the laws of Sri Lanka)
|
Cantel Medical (Italy) S.r.l.
|
(Incorporated under the laws of Italy)
|
Cantel Medical Devices (China) Co., Ltd.
|
(Incorporated under the laws of China)
|
Cantel (UK) Limited
|
(Incorporated under the laws of England and Wales)
|
Medical Innovations Group Limited
|
(Incorporated under the laws of England and Wales)
|
Medi-Cart International Limited
|
(Incorporated under the laws of England and Wales)
|
Accutron, Inc.
|
(Incorporated under the laws of Arizona)
|
Cantel Medical (Hong Kong) Limited
|
(Incorporated under the laws of Hong Kong)
|
Cantel Medical (Malaysia) Sdn. Bhd.
|
(Incorporated under the laws of Malaysia)
|
Cantel Middle East FZ-LLC
|
(Incorporated under the laws of Dubai (UAE))
|
Cantel (Germany) GmbH
|
(Incorporated under the laws of Germany)
|
Cantel (France) SAS
|
(Incorporated under the laws of France)
|
Cantel (Australia) PTY LTD
|
(Incorporated under the laws of Australia)
|
TIV Technisches Institut fur Validierung GmbH
|
(Incorporated under the laws of Germany)
|
Cantel (Production) Germany GmbH
|
(Incorporated under the laws of Germany)
|
BHT Hygienetechnik Holding GmbH
|
(Incorporated under the laws of Germany)
|
BHT Hygienetechnik GmbH
|
(Incorporated under the laws of Germany)
|
Omnia S.r.l.
|
(Incorporated under the laws of Italy)
|
Bior Medica S.r.l.
|
(Incorporated under the laws of Italy)
|
Omnia Dental S.L.
|
(Incorporated under the laws of Spain)
|
Camark S.A.
|
(Incorporated under the laws of Greece)
|
Omnia LLC
|
(Incorporated under the laws of Pennsylvania)
|
Jet Prep. Ltd
|
(Incorporated under the laws of Israel)
|
(1)
|
Registration Statements (Form S-8 Nos. 333-140388, 333-157033, 333-163806 and 333-180171) pertaining to the Cantel Medical Corp. 2006 Equity Incentive Plan, as amended, and
|
1.
|
I have reviewed this Annual Report on Form 10-K of Cantel Medical Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
|
By:
|
/s/ George L. Fotiades
|
George L. Fotiades, President and Chief Executive Officer (Principal Executive Officer)
|
1.
|
I have reviewed this Annual Report on Form 10-K of Cantel Medical Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
|
By:
|
/s/ Shaun M. Blakeman
|
Shaun M. Blakeman, Senior Vice President and Chief Financial Officer
|
1.
|
The Form 10-K fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ George L. Fotiades
|
George L. Fotiades
|
President and Chief Executive Officer
|
(Principal Executive Officer)
|
|
/s/ Shaun M. Blakeman
|
Shaun M. Blakeman
|
Senior Vice President, Chief Financial Officer
|
(Principal Financial Officer)
|